Riccardo Vernuccio

Dr. Riccardo Vernuccio

Structural Biology of Infectious Diseases group, Institut Pasteur, Paris, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
Riccardo VernuccioRiccardo Vernuccio
Riccardo Vernuccio
ALAlejandro Martínez León
Alejandro Martínez León
Chetan PoojariChetan Poojari
Chetan Poojari
JBJulian Buchrieser
Julian Buchrieser
CSChristopher N. Selverian
Christopher N. Selverian
Pablo Guardado-CalvoPablo Guardado-Calvo
Pablo Guardado-Calvo
Mpox is a zoonotic disease endemic to Central and West Africa. Since 2022, two human-adapted monkeypox virus (MPXV) strains have caused large outbreaks outside these regions. Tecovirimat is the most widely used drug to treat mpox. It blocks viral egress by targeting the viral phospholipase F13; however, the structural details are unknown, and mutations in the F13 gene can result in resistance against tecovirimat, raising public health concerns. Here we report the structure of an F13 homodimer using X-ray crystallography, both alone (2.1 Å) and in complex with tecovirimat (2.6 Å). Combined with molecular dynamics simulations and dimerization assays, we show that tecovirimat acts as a molecular glue that promotes dimerization of the phospholipase. Tecovirimat resistance mutations identified in clinical MPXV isolates map to the F13 dimer interface and prevent drug-induced dimerization in solution and in cells. These findings explain how tecovirimat works, allow for better monitoring of resistant MPXV strains and pave the way for developing more potent and resilient therapeutics.

8 December 2023 in Viruses
Verified
Journal Article
Open access
PDF file
Riccardo VernuccioRiccardo Vernuccio
Riccardo Vernuccio
Pablo Guardado-CalvoPablo Guardado-Calvo
Pablo Guardado-Calvo
Smallpox was a highly contagious disease caused by the variola virus. The disease affected millions of people over thousands of years and variola virus ranked as one of the deadliest viruses in human history. The complete eradication of smallpox in 1980, a major triumph in medicine, was achieved through a global vaccination campaign using a less virulent poxvirus, vaccinia virus. Despite this success, the herd immunity established by this campaign has significantly waned, and concerns are rising about the potential reintroduction of variola virus as a biological weapon or the emergence of zoonotic poxviruses. These fears were further fueled in 2022 by a global outbreak of monkeypox virus (mpox), which spread to over 100 countries, thereby boosting interest in developing new vaccines using molecular approaches. However, poxviruses are complex and creating modern vaccines against them is challenging. This review focuses on the structural biology of the six major neutralization determinants on poxviruses (D8, H3, A27, L1, B5, and A33), the localization of epitopes targeted by neutralizing antibodies, and their application in the development of subunit vaccines.

23 January 2025 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JPJeanne Postal
Jeanne Postal
FGFlorence Guivel-Benhassine
Florence Guivel-Benhassine
FPFrançoise Porrot
Françoise Porrot
QGQuentin Grassin
Quentin Grassin
JCJack M Crook
Jack M Crook
OSOlivier Schwartz
Olivier Schwartz

26 August 2025 in Cell
Verified
Journal Article
Open access
AMAnnalisa Meola
Annalisa Meola
Riccardo VernuccioRiccardo Vernuccio
Riccardo Vernuccio
LBLeandro Battini
Leandro Battini
GAGuillermo Albericio
Guillermo Albericio
PDPilar Delgado
Pilar Delgado
Pablo Guardado-CalvoPablo Guardado-Calvo
Pablo Guardado-Calvo
Monkeypox virus (MPXV) is a poxvirus endemic to Central and West Africa with high epidemic potential. Poxviruses enter host cells via a conserved entry-fusion complex (EFC), which mediates viral fusion to the cell membrane. The EFC is a promising therapeutic target, but the absence of structural data has limited the development of fusion-inhibiting treatments. Here, we investigated A16/G9, a subcomplex of the EFC that controls fusion timing. Using cryo-electron microscopy, we showed how A16/G9 interacts with A56/K2, a viral fusion suppressor that prevents superinfection. Immunization with A16/G9 elicited a protective immune response in mice. Using X-ray crystallography, we characterized two neutralizing antibodies and engineered a chimeric antibody that cross-neutralizes several poxviruses more efficiently than 7D11, the most potent antibody targeting the EFC described to date. These findings highlight the potential of A16/G9 as a candidate for subunit vaccines and identify regions of the EFC as targets for antiviral development.

15 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJiannan Chen
Jiannan Chen
LHLiyuan Hu
Liyuan Hu
Riccardo VernuccioRiccardo Vernuccio
Riccardo Vernuccio
NSNing Shi
Ning Shi
JTJiaxin Tian
Jiaxin Tian
RZRong Zhang
Rong Zhang
The recent global outbreaks of mpox highlight the urgent need for both fundamental research and antiviral development. However, studying the mpox virus (MPXV), with its large and complex genome, remains challenging due to the requirement for high-containment facilities. Here, we describe a strategy for de novo assembly of MPXV clade IIb genomes in bacterial artificial chromosomes using transformation-associated recombination cloning. Leveraging CRISPR-Cas9 and Lambda Red recombination, we engineer replication-defective MPXV particles with dual deletions of OPG96 (M2R) and OPG158 (A32.5 L)—genes essential for virion assembly, that are capable of recapitulating key stages of the viral life cycle. We apply this system to screen a compound library and identify G243-1720, a potent anti-poxvirus inhibitor with broad activity in vitro and in vivo. G243-1720 blocks the formation of extracellular enveloped virions and cell-cell spread. Resistance mutation selection, crystallographic analysis, analytical ultracentrifugation, and mass photometry reveal that, despite its distinct chemical structure, G243-1720 shares a mode of action with tecovirimat, both functioning by affecting dimerization of protein OPG57 (F13). Our findings underscore the potential of G243-1720 as a promising broad-spectrum anti-poxvirus lead compound and demonstrate the utility of replication-defective MPXV particles as a reliable platform for viral biology studies and antiviral development.

23 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
Riccardo VernuccioRiccardo Vernuccio
Riccardo Vernuccio
ALAlejandro Martínez León
Alejandro Martínez León
Chetan PoojariChetan Poojari
Chetan Poojari
JBJulian Buchrieser
Julian Buchrieser
CSChristopher Selverian
Christopher Selverian
PGPablo Guardado-Calvo
Pablo Guardado-Calvo
Mpox is a zoonotic disease endemic in central and west Africa. However, since 2022, human-adapted mpox virus (MPXV) strains are causing large outbreaks spreading outside these regions, leading the World Health Organization to declare public health emergency twice. Tecovirimat, the most widely used drug to treat these infections, blocks viral egress through a poorly understood mechanism. Tecovirimat-resistant strains, all with mutations in the viral phospholipase F13, pose public health concerns. Herein, we report the structure of an F13 homodimer, both alone and in complex with tecovirimat. We demonstrate that tecovirimat acts as a molecular glue, inducing the dimerization of the phospholipase. F13 escape mutations in MPXV clinical isolates are at the dimer interface and prevent drug-induced dimerization in solution and cells. These findings, which decipher tecovirimat's mode of action, will allow better monitoring of poxvirus outbreaks and pave the way for developing more potent and resilient therapeutics.